The Munich-based healthcare startup Temedica has raised €17 million. With this Series B financing, the startup aims to further consolidate its position as an innovation driver in the rapidly growing digital health market. Lead investors are MIG Fonds, Santo Venture Capital, and Salvia. Existing shareholders such as Bernd Wendeln and G+J Digital Ventures have also reinvested.
The Digital Health-Company Temedica has successfully closed its Series B financing round of €17 million, led by MIG Fund, Santo Venture Capital and Salvia. The last financing round was already in the seven-digit range and was about two years ago.
The Munich-based startup develops digital therapy companions. Temedica's current market offerings include Pelvina, an app for pelvic floor training; Mineo, a back-training app; and Waya, a tool for healthy nutrition and exercise. These apps are designed to support patients in their healing and sustainable medical care. Some products are being developed in collaboration with partners.
Apps for the digital health market
With this investment, Temedica aims to further advance its app development platform and cover additional indications, particularly in the area of chronic diseases.
Gloria Seibert, founder and CEO at Temedica, says:
"With this investment, we are able to continue our growth and develop digital patient companions for new indications. I am pleased that we have been able to improve the health of many people to date and provide significant added value for patients."
Seibert is also relying on its cooperation partners and investors for the upcoming organizational expansion and expertise in the healthcare market. Michael Motschmann, partner at lead investor MIG, says:
"With Temedica's intelligent digital approach, we are complementing our traditionally strong foothold in the healthcare sector. We want to participate in the great potential of the future market for digital health services."
